PathGroup, a provider of anatomic, clinical, digital, and molecular pathology services, will advance its standard of diagnosis for diseases like cancer through Proscia’s Concentriq Dx digital pathology software platform.

PathGroup is expanding its operations with Proscia’s software platform to further enhance the delivery of fast, high quality results for millions of patients, helping to better inform treatment decisions, according to the companies.

Up to 70% of clinical decisions depend on pathology.[1] Digital pathology shifts diagnosis from microscope to whole slide image, unlocking insights previously unseen by the human eye to realize the promise of precision medicine. It also drives powerful efficiency gains that are helping laboratories to overcome a range of systemic challenges; the number of cancer cases is expected to rise 47% between 2020 and 2040[2] while only 65% of pathology groups looking to hire could fill all open roles in 2021[3].

“Taking this next step on our journey requires a company to serve as our trusted partner and a platform that will grow across our network,” says Ben W. Davis, MD, CEO of PathGroup. “After a robust evaluation, we are thrilled that Proscia shares our vision for a fully digital future and confident that Concentriq Dx will enable us to rapidly expand upon our existing digital pathology foundation. With Proscia’s nimbleness and speed to innovation, we will leverage the latest technology, including AI, to provide the next generation of diagnosis for millions of patients.”

Concentriq Dx* is a modern pathology platform that drives routine diagnosis for laboratory networks of all sizes. By streamlining collaboration and enabling remote image viewing, its aimed to empower pathologists to deliver higher quality results through broadened access to expertise.

“PathGroup’s transition to Concentriq Dx is a testament to the platform’s ability to deliver on the full promise of digital pathology at scale,” says David West, Proscia’s CEO. “Pathology data is one of healthcare’s most valuable assets, and PathGroup is now well-positioned to fully capitalize on its potential to transform patient care.”

PathGroup currently supports more than 15,000 referring physicians and over 200 hospital customers with diversified laboratory testing services and high-touch customer service. Its team of more than 225 pathologists represents every pathology subspecialty. PathGroup operates a fully digital primary diagnosis approach at its centralized laboratory in Nashville, Tenn.

“Digital pathology is quickly becoming synonymous with pathology,” says Steve Holloway, company director at Signify Research. “As leading laboratories like PathGroup grow their implementations, they continue to set a new standard of diagnosis.”

*Concentriq Dx is CE-marked under IVDR and is available for primary diagnosis in the US during the COVID-19 public health emergency. 

Featured image: PathGroup will advance the 150-year-old standard of diagnosis for diseases like cancer with Proscia’s Concentriq Dx software platform. Photo: Proscia


[1] NHS England (2017). Digital First: Clinical Transformation Through Pathology Innovation. National Pathology Programme; doi:

[2] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660

[3] Gross, D. et al (2022). Strong Job Market for Pathologists: Results From the 2021 College of American Pathologists Practice Leader Survey. Arch Pathol Lab Med 2022; doi: